New-Onset Lymphopenia Assessed during Routine Follow-up Is a Risk Factor for Relapse Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma

ROC curve to evaluate ALC at follow-up post-APHSCT as a marker for relapse. Specifically, this curve plots the sensitivity versus 1 minus the specificity of this marker for relapse. The corresponding AUC analysis indicated that ALC at follow-up post-APHSCT was indeed a significant marker for relapse (AUC=0.86, P < .0001).

Cumulative incidence for relapse based on ALC at follow-up post APHSCT. Patients with an ALC <1.0×10⁹/L at follow-up experienced a higher cumulative incidence of 92% compared with a cumulative incidence of 19% for patients with an ALC ≥1.0×10⁹/L at follow-up post-APHSCT.

Scatterplot comparing ALC at follow-up and LDH at follow-up post-APHSCT. A negative correlation was identified between ALC and LDH at follow-up post-APHSCT. Arrows indicate those points that according to the Mahalanobis distances are outliers. R1 and R2 correspond to the Pearson' r values before and after eliminating possible outliers. The regression line was estimated after the elimination of outliers.

Cumulative incidence for relapse based on the ALC and LDH at follow-up post-APHSCT. Patients with an ALC <1.0×10⁹/L experienced a higher cumulative incidence of relapse regardless if the LDH was normal or abnormal at follow-up compared with a lower cumulative incidence of relapse with an ALC ≥1.0×10⁹/L regardless if the LDH was normal or abnormal at follow-up post-APHSCT.